Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

BofA Securities reiterated its Buy rating on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), with a steady price target of GBP145.00. The firm's positive stance is based on the pharmaceutical giant's ...

Recognising that challenge, AstraZeneca's rare disease unit Alexion has launched an interactive storybook that can help ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

Alexion, AstraZeneca Rare Disease, and DHL Express announced a partnership to reduce greenhouse gas emissions (GHG) from the ...

Morgan Stanley analyst Sarita Kapila initiated coverage of AstraZeneca (AZN) with an Overweight rating and 14,500 GBp price target The firm ...

The Prime Minister Narendra Modi delivered his remarks at the India Energy Week 2025 via video message yesterday. Highlighting that experts worldwide are asserting that the 21st century belongs to ...

Astrazeneca Pharma India advanced 1.21% to Rs 7557.05 after the company's standalone net profit surged to Rs 54.68 crore in Q3 FY25 as compared with Rs 15.80 crore in Q3 FY24.

In this video, we analyze the latest Q3 earnings and key developments from top stocks to watch. TVS Motor has signed an MoU with the Karnataka Government to invest ₹2,000 crore over the next five ...

The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...